Orthomyxoviridae (e.g., Influenza Virus, Fowl Plague Virus, Etc.) Patents (Class 424/209.1)
-
Patent number: 9278126Abstract: Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12 ?g/ml per strain. In some embodiments the squalene concentration is <19 mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3 mL. In some embodiments the squalene concentration is 9.75 mg/mL or 4.88 mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.Type: GrantFiled: February 10, 2010Date of Patent: March 8, 2016Assignee: Seqirus UK LimitedInventors: Mario Contorni, Derek O'hagan, Nicola Groth
-
Patent number: 9216211Abstract: This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered.Type: GrantFiled: July 11, 2013Date of Patent: December 22, 2015Assignee: MERIAL, INC.Inventor: Benjamin M Hause
-
Patent number: 9150620Abstract: The present invention relates to a recombinant DNA molecule encoding a mutated hemagglutinin protein, wherein the mutated hemagglutinin protein consists of the amino acid sequence of SEQ ID NO: 2 with one or more mutations at amino acid residue selecting from the group consisting of residue 83, 127, 138 and the combination thereof. The present invention also relates to a composition comprising the recombinant DNA molecule as described above and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. The present invention further relates to a kit for prime-boost vaccination, comprising at least a composition comprising a recombinant DNA molecule as described above and at least a composition for the boost-vaccination comprising a recombinant hemagglutiinin protein or a virus-like particle, wherein the recombinant hemagglutiinin protein is the corresponding hemagglutiinin protein encoded by the recombinant DNA molecule.Type: GrantFiled: March 19, 2014Date of Patent: October 6, 2015Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Suh-Chin Wu, Shih-Chang Lin
-
Patent number: 9138471Abstract: The invention relates to methods for one-dose influenza vaccine for intradermal delivery of a trivalent, non-live influenza antigen preparation, particularly a split influenza preparation.Type: GrantFiled: October 12, 2011Date of Patent: September 22, 2015Assignee: GlaxoSmithKline Biologicals, S.A.Inventors: Nathalie Garcon, Moncef Mohamed Slaoui, Christian Van Hoecke
-
Patent number: 9089537Abstract: The present disclosure generally relates to vaccine compositions for Herpes Simplex Viruses (HSV) types 1 and/or 2. The vaccines comprise isolated antigens or glycoprotein subunits of the viruses, optionally with an adjuvant, such as a cationic liposome DNA complex (CLDC). Also the present disclosure contains methods of vaccinating a subject utilizing these compositions.Type: GrantFiled: February 25, 2011Date of Patent: July 28, 2015Assignees: The Trustees of the University of Pennslyvania, Juvaris Biotherapeutics, Inc.Inventors: Jeffery Fairman, Gary H. Cohen, Roselyn J. Eisenberg
-
Patent number: 9072701Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined hemagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.Type: GrantFiled: April 18, 2007Date of Patent: July 7, 2015Assignees: St. Jude Children's Research Hospital, Zoetis Services LLCInventors: Erich Hoffmann, Scott L. Krauss, Mahesh Kumar, Richard J. Webby, Robert G. Webster
-
Patent number: 9040296Abstract: The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.Type: GrantFiled: March 17, 2012Date of Patent: May 26, 2015Assignee: ValnevaInventors: Majid Mehtali, Patrick Champion-Arnaud, Arnaud Leon
-
Publication number: 20150140036Abstract: The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, e.g., with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.Type: ApplicationFiled: November 13, 2014Publication date: May 21, 2015Applicant: NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.Inventors: Joan Mannick, David Glass, Leon Murphy
-
Patent number: 9028838Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: March 4, 2013Date of Patent: May 12, 2015Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Patent number: 9023319Abstract: Provided herein are methods for immunizing children under six months of age by administering to the child a pharmaceutical composition comprising at least one antigen derived from an influenza virus.Type: GrantFiled: October 12, 2007Date of Patent: May 5, 2015Assignee: Sanofi Pasteur Inc.Inventor: Michael Decker
-
Publication number: 20150118264Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.Type: ApplicationFiled: January 31, 2013Publication date: April 30, 2015Applicant: CureVac GMBHInventors: Patrick Baumhof, Thomas Kramps, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
-
Patent number: 9011874Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: November 22, 2010Date of Patent: April 21, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy Jones
-
Patent number: 9005623Abstract: The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group.Type: GrantFiled: October 7, 2008Date of Patent: April 14, 2015Assignee: Sanofi Pasteur, SAInventors: Catherine Moste, Isabelle Legastelois, Michel Chevalier, Laurent Thion
-
Patent number: 9005632Abstract: Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject.Type: GrantFiled: July 20, 2012Date of Patent: April 14, 2015Assignee: Takeda Vaccines, Inc.Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Timothy D. Powell, Jeremy C. Jones, Joseph N. Brewoo
-
Patent number: 9005621Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: GrantFiled: July 3, 2014Date of Patent: April 14, 2015Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H. J. Kwaks
-
Publication number: 20150098966Abstract: An influenza vaccine comprising an influenza hemagglutinin-containing antigen which is subjected to a treatment at a suitable low pH or other suitable conditions to obtain a suitable degree of loss of potency, and the method of making it are provided. The vaccine not only induces an increased cross-reactive immune response and cross protection, but can also induce a strain-specific immune response and protection like current inactivated vaccines. A method of administering influenza vaccines is also provided to induce an increased cross-reactive immune response and cross protection, which is especially suitable for use in emergency situations such as a pandemic.Type: ApplicationFiled: May 14, 2013Publication date: April 9, 2015Applicant: KJ Biosciences LLCInventors: Yawei Ni, Jianhua Guo
-
Patent number: 8999353Abstract: A method for eliciting or inducing a protective immune response in a subject against a pandemic subtype of influenza virus comprises administering to the subject a composition comprising (i) at least one immunogen of an endemic influenza subtype, and (ii) an immunogen-free immunostimulating complex as adjuvant.Type: GrantFiled: October 9, 2008Date of Patent: April 7, 2015Assignee: CSL LimitedInventors: Martin Pearse, Steve Rockman, David Ryan
-
Patent number: 8999352Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: November 23, 2011Date of Patent: April 7, 2015Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 8993624Abstract: The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.Type: GrantFiled: May 26, 2011Date of Patent: March 31, 2015Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Josep Bassaganya-Riera, Amir Guri, Raquel Hontecillas
-
Patent number: 8992939Abstract: This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.Type: GrantFiled: October 24, 2011Date of Patent: March 31, 2015Assignee: Novavax, Inc.Inventors: Gale Smith, Yingyun Wu, Michael Massare, Peter Pushko, Margret Nathan, Thomas Kort, Robin Robinson
-
Publication number: 20150086560Abstract: The present invention is directed generally to M1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-M1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-M1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response.Type: ApplicationFiled: September 21, 2014Publication date: March 26, 2015Inventors: Mark R. AIfenito, Mark Baer, Doris Bucher
-
Publication number: 20150086587Abstract: Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil. The adjuvant emulsions can be used to potentiate the immunological effects of active agents, including antigens derived from various pathogens and/or toxins. Immunogenic compositions comprising the adjuvant emulsions and various active agents are also provided, along with vaccine systems for therapeutic or prophylactic treatment of a subject using these adjuvants.Type: ApplicationFiled: March 28, 2013Publication date: March 26, 2015Inventors: Jishu Shi, Loretta Pappan, Amy Beckley, Qixin Zhong
-
Patent number: 8986705Abstract: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.Type: GrantFiled: February 27, 2013Date of Patent: March 24, 2015Assignee: MedImmune, LLCInventors: George Robert Trager, Vu Truong-Le, Luisa Yee
-
Patent number: 8986987Abstract: The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector.Type: GrantFiled: October 17, 2011Date of Patent: March 24, 2015Assignee: Intervet Inc.Inventors: Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
-
Patent number: 8980281Abstract: Virus-like particles (VLPs) of mammalian-hosted viruses, such as SARS-CoV and influenza viruses, have been recombinantly produced from Vero cells. The VLPs closely emulate the exterior of authentic virus particles and are highly immunogenic. They can elicit not only humoral but also cellular immune responses in a mammal. Compositions and methods related to the VLPs are also described.Type: GrantFiled: February 12, 2010Date of Patent: March 17, 2015Assignee: Academia SinicaInventors: Pei-Wen Hsiao, Chia-Ying Wu, Yi-Chun Yeh
-
Publication number: 20150064216Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.Type: ApplicationFiled: November 11, 2014Publication date: March 5, 2015Inventors: William A. CARTER, David STRAYER
-
Publication number: 20150056235Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: ApplicationFiled: October 6, 2014Publication date: February 26, 2015Inventors: PATTI CYNTHIA CRAWFORD, PAUL J. GIBBS, EDWARD J. DUBOVI, RUBEN OMAR DONIS, JACQUELINE KATZ, ALEXANDER I. KLIMOV, NALLAKANNU P. LAKSHMANAN, MELISSA ANNE LUM, DANIEL GHISLENA EMIEL GOOVAERTS, MARK WILLIAM MELLENCAMP, NANCY J. COX, WILLIAM L. CASTLEMAN
-
Publication number: 20150056249Abstract: The present invention relates to influenza vaccine compositions and vaccination schemes for immunizing against influenza disease, in particular it relates to immunogenic compositions comprising an antigen or a antigenic preparation from a first influenza virus strain and an oil-in-water emulsion adjuvant for use in inducing a immune response against at least one second influenza virus strain wherein said second influenza virus strain is from a different type or from a different subtype than said first influenza virus strain.Type: ApplicationFiled: March 13, 2013Publication date: February 26, 2015Inventors: Bruce Lamont Innis, Sumita Roy-Ghanta
-
Publication number: 20150050307Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.Type: ApplicationFiled: March 29, 2013Publication date: February 19, 2015Inventors: Christopher James Nicolai, Semih U. Tareen
-
Patent number: 8951537Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: November 15, 2011Date of Patent: February 10, 2015Assignee: Novavax, Inc.Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
-
Publication number: 20150037355Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.Type: ApplicationFiled: January 4, 2012Publication date: February 5, 2015Applicants: SILLAJEN, INC., JENNEREX INC.Inventors: David Kirn, John Bell, Caroline Breitback, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
-
Publication number: 20150037352Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.Type: ApplicationFiled: October 16, 2014Publication date: February 5, 2015Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
-
Patent number: 8945590Abstract: This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method.Type: GrantFiled: March 25, 2009Date of Patent: February 3, 2015Assignee: Juvaris BioTherapeutics, Inc.Inventors: Jeffery Fairman, Marla Lay Vaughn
-
Patent number: 8945579Abstract: Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. Compositions administered to the subject can further include a carrier and can be administered in single or multiple doses.Type: GrantFiled: February 6, 2013Date of Patent: February 3, 2015Assignee: VaxInnate CorporationInventors: Langzhou Song, Valerian Nakaar, Albert E. Price, Lynda G. Tussey, James W. Huleatt, Thomas J. Powell, Robert K. Evans
-
Publication number: 20150030642Abstract: The invention discloses a polymer micro-needle array chip, comprising a substrate and a micro-needle array standing thereon; the material for preparing the micro-needle array is a polyacrylamides polymer, with the molecular weight of 1.0×104-2.0×105, the Vickers hardness of 150-600 HV, and the impact strength of 5-30 J/m. The polymer micro-needle array chip has a high mechanical strength and a sharp needle tip, and it can easily dissolve or swell on contact with a water-containing environment, which helps the drug to be released slowly in the skin.Type: ApplicationFiled: May 25, 2012Publication date: January 29, 2015Applicant: Technical Institute of Physics and Chemistry of the Chinese Academy of SciencesInventors: Feipeng Wu, Yuanhua Miao
-
Patent number: 8940307Abstract: The present invention also relates to a method of reducing metastases in a subject comprising administering to the subject a composition comprising a multifunctional molecule comprising a first part which is capable of binding to an antigen bearing target and a second part which is capable of binding to a cell.Type: GrantFiled: September 19, 2003Date of Patent: January 27, 2015Assignee: Opsanitx LLCInventors: Andrew H. Segal, Elihu Young
-
Publication number: 20150024002Abstract: Described herein are compositions and methods for stimulating an immune response to one or more proteins derived from one or more respiratory pathogens. In particular, the invention relates to alphavirus replicons, alphavirus vector constructs, alphavirus replicon particles expressing one or more antigens derived from one or more respiratory pathogens as well as to method of making and using these immunogenic compositions.Type: ApplicationFiled: August 20, 2014Publication date: January 22, 2015Inventors: Silvia Perri, John Polo, Yasushi Uematsu, Catherine Greer
-
Publication number: 20150017205Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.Type: ApplicationFiled: July 15, 2014Publication date: January 15, 2015Inventors: Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping
-
Patent number: 8932597Abstract: The present invention provides novel peptide immunogens comprising influenza virus matrix 2 protein epitopes and related compositions and methods. The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of an influenza virus-mediated disease. The invention also relates to vaccines, immunogenic products and immunogenic compositions containing the peptide immunogens.Type: GrantFiled: June 14, 2012Date of Patent: January 13, 2015Assignee: Theraclone Sciences, Inc.Inventors: Matthew Moyle, Jennifer Mitcham
-
Publication number: 20150010595Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: ApplicationFiled: June 11, 2014Publication date: January 8, 2015Applicant: Valneva Austria GmbHInventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Patent number: 8927270Abstract: The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection.Type: GrantFiled: March 28, 2008Date of Patent: January 6, 2015Assignee: Zeon CorporationInventors: Motoyuki Esaki, Lauren Elizabeth Jensen, Kristi M. Dorsey
-
Publication number: 20140377308Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.Type: ApplicationFiled: August 25, 2014Publication date: December 25, 2014Inventors: Julia ROMANOVA, Andrej EGOROV, Brigitte KRENN, Markus WOLSCHEK, Sabine NAKOWITSCH
-
Patent number: 8916160Abstract: The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.Type: GrantFiled: February 14, 2012Date of Patent: December 23, 2014Assignee: Theraclone Sciences, Inc.Inventors: Andres G. Grandea, III, Gordon King, Thomas C. Cox, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Phil Hammond
-
Patent number: 8916519Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: GrantFiled: June 24, 2014Date of Patent: December 23, 2014Assignees: Rutgers, The State University of New Jersey, Board of Regents, The University of Texas SystemInventors: Gaetano T. Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Publication number: 20140370053Abstract: An influenza vaccine is administered by a multi-dose regimen, in which (i) a first dose is administered with an adjuvant and (ii) a later dose is administered either without an adjuvant or with a different adjuvant. Thus the invention provides the benefits of a two-dose regimen without also doubling the supply need for a given adjuvant.Type: ApplicationFiled: July 8, 2014Publication date: December 18, 2014Inventors: Giuseppe DEL GIUDICE, Riccardo MANETTI
-
Publication number: 20140363474Abstract: The present invention relates to influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to multivalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from at least two influenza virus strains, at least one strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant.Type: ApplicationFiled: August 21, 2014Publication date: December 11, 2014Inventors: Emmanuel Jules HANON, Jean STEPHENNE
-
Publication number: 20140363467Abstract: The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lin28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.Type: ApplicationFiled: December 9, 2013Publication date: December 11, 2014Applicant: University of Georgia Research Foundation, Inc.Inventors: Steven L. Stice, Franklin West, Yangqing Lu
-
Publication number: 20140356408Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and volatile organic solvents, yet the carbohydrate-glass particles are insoluble in organic solvents. A method for formulation of the polymeric compositions containing ambient-temperature stable biopharmaceuticals includes combining biopharmaceuticals encapsulated in carbohydrate-glass particles with polymer in organic solvent and evaporating the organic solvent to yield a water soluble polymeric composition containing ambient-temperature stable biopharmaceuticals.Type: ApplicationFiled: May 30, 2014Publication date: December 4, 2014Inventor: Victor Bronshtein
-
Patent number: 8900585Abstract: Disclosed herein are neutralizing antibodies with cross-neutralizing activity and cross-protective effects against divergent stains of influenza virus, which are specific for an epitope having at least 90% homology to amino acids +72-115 of the HA1 domain of H5N1 influenza virus hemagglutinin.Type: GrantFiled: October 20, 2011Date of Patent: December 2, 2014Assignee: New York Blood Center, Inc.Inventors: Shibo Jiang, Lanying Du, Yusen Zhou
-
Patent number: 8900590Abstract: The present invention provides novel human anti-Influenza antibodies and related compositions and methods. These antibodies are used in the prevention, inhibition, neutralization, diagnosis, and treatment of influenza infection.Type: GrantFiled: August 12, 2011Date of Patent: December 2, 2014Assignee: Theraclone Sciences, Inc.Inventors: Ole Olsen, Christina L. Boozer, Andres G. Grandea, III